Ligand News and Research

RSS

Review explores WNT5B and WNT10B roles in osteosarcoma

A new review was published in Oncotarget's Volume 15 on August 2, 2024, entitled, "Targeting WNT5B and WNT10B in osteosarcoma."

4 Sep 2024

Scientists discover key to activating natural killer cells against cancer

Scientists are on the verge of a cancer breakthrough after working out how the body's immune system targets cells devastated by the disease.

28 Aug 2024

Maternal gut bacteria linked to changes in fetal brain metabolism

The impact of Bifidobacterium breve's presence in the maternal gut during pregnancy on fetal brain metabolism.

23 Aug 2024

How persistent organic pollutants affect gut health: findings on metabolic disruptions and microbiota changes

Early life exposure to potent AHR agonists on gut microbiota and its potential effects on metabolic health later in life.

20 Aug 2024

New targets for improved cancer immunotherapy

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptors with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4. By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients.

14 Aug 2024

AlphaFold accelerates discovery of potential antipsychotic drugs by outperforming traditional methods

Researchers used AlphaFold and homology modeling to identify potent TAAR1 agonists, showing AlphaFold's superior performance in drug discovery for neuropsychiatric conditions.

13 Aug 2024

Review of fasting-mimicking diets in cancer treatment

Researchers present the role of cyclic fasting and fasting-mimicking diets (FMD) in cancer therapy.

8 Aug 2024

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.

From Sino Biological Inc. 5 Aug 2024

Study elucidates mechanisms behind G protein selectivity and efficacy in adenosine A2A receptor

In a groundbreaking study, a multinational research team led by Dr. Adnan Sljoka (RIKEN) and Prof. Akio Kitao (Tokyo Tech), in collaboration with Prof. Scott Prosser (University of Toronto), has carried out experimental and computational studies to elucidate the mechanisms behind G protein selectivity and efficacy in the human adenosine A2A receptor (A2AR).

1 Aug 2024

Study unveils dual roles of TNF-α receptors in tissue regeneration and cell death

A study published in The EMBO Journal opens new perspectives to better understand how the molecular mechanisms involved in regenerative medicine work.

29 Jul 2024

Study finds genetic factors key to post-stroke cardiovascular risks

Research identifies genetic and molecular risk factors for cardiovascular outcomes after an initial stroke, uncovering potential therapeutic targets to improve patient prognoses.

28 Jul 2024

Proteomic signatures enhance risk prediction for both common and rare diseases

Researchers have developed sparse prediction models combining plasma proteins and clinical data to predict the 10-year risk of 218 diseases. The study, involving over 41,000 participants, highlights the enhanced predictive power of proteomic signatures.

24 Jul 2024

Concussions in retired rugby players linked to higher neurodegenerative disease biomarkers

A study in the International Journal of Molecular Sciences reveals that retired rugby players with a history of concussions exhibit significant differences in biomarkers associated with neurodegenerative diseases compared to non-contact sports participants.

21 Jul 2024

Leveraging antibodies as a drug delivery mechanism may prove useful in the treatment of cancers

The primary goal in cancer drug research is not merely to discover compounds that can destroy cancer cells, but to develop methods that specifically target and deliver these agents to cancer cells, sparing healthy ones.

11 Jul 2024

Researchers identify shared molecular mechanism in cancer and pregnancy that suppresses immune system

Researchers elucidated the shared immune tolerance mechanisms in cancer and pregnancy, focusing on the role of an immune checkpoint protein as an onco-fetal immune tolerance checkpoint.

11 Jul 2024

Innovative research sheds light on migraine mechanisms and potential therapies

New research describes for the first time how a spreading wave of disruption and the flow of fluid in the brain triggers headaches, detailing the connection between the neurological symptoms associated with aura and the migraine that follows.

4 Jul 2024

Frequent infections and pathobionts boost children's nasal immunity, study reveals

Dynamic interactions with viruses and bacterial pathobionts significantly enhance nasal innate immunity in children, revealing distinct immunophenotypes driven by microbial load and type.

2 Jul 2024

Advancements in immunotherapy for hepatocellular carcinoma offer hope to patients

Hepatocellular carcinoma (HCC) is a primary liver cancer predominantly arising from chronic liver diseases such as hepatitis B and C infections, alcohol abuse, and metabolic disorders.

2 Jul 2024

Optibrium demonstrates accelerated lead optimization in complex agrochemical development

Optibrium, a leading developer of software and AI solutions for molecular design today announced the publication of a peer-reviewed study in Journal of Computer-Aided Molecular Design, ‘From UK-2A to florylpicoxamid: Active learning to identify a mimic of a macrocyclic natural product’

From Optibrium Ltd. 2 Jul 2024

New study reveals key to more effective antihistamines

Even if two molecules have the exact same chemical formula and the same number and types of bonds, their three-dimensional arrangements can still be different.

1 Jul 2024